How do you incorporate CAR-T cell therapy in the second line setting for DLBCL patients who are eligible for consolidative autologous transplant?   

Does the result of their salvage chemotherapy and whether PR or CR is acheived affect your decision?



Answer from: Medical Oncologist at Academic Institution